[PART I - FINANCIAL INFORMATION](index=5&type=section&id=PART%20I%20-%20FINANCIAL%20INFORMATION) This part details the company's financial performance, condition, and cash flows, along with management's analysis and market risk disclosures [Financial Statements](index=5&type=section&id=Item%201.%20Financial%20Statements) The unaudited condensed consolidated financial statements for Avadel Pharmaceuticals plc for Q2 and H1 2025 and 2024 are presented, including income, comprehensive income, balance sheets, equity, cash flows, and detailed notes [Summary of Significant Accounting Policies](index=11&type=section&id=NOTE%201%3A%20Summary%20of%20Significant%20Accounting%20Policies) The company is a biopharmaceutical firm whose sole commercial product is LUMRYZ, an extended-release sodium oxybate for treating cataplexy or EDS in narcolepsy patients - LUMRYZ was approved by the FDA for adults with narcolepsy on **May 1, 2023**, and for pediatric patients (age 7+) on **October 16, 2024**[35](index=35&type=chunk) - The company has initiated a pivotal Phase 3 trial, REVITALYZ, to evaluate LUMRYZ for the treatment of Idiopathic Hypersomnia (IH)[37](index=37&type=chunk) - LUMRYZ was granted Orphan Drug Designation (ODD) by the FDA for the treatment of IH on **June 5, 2025**[37](index=37&type=chunk) [Revenue Recognition](index=14&type=section&id=NOTE%202%3A%20Revenue%20Recognition) All net product revenue for the reported periods is derived from U.S. sales of LUMRYZ, with sales highly concentrated among three customers Percentage of Total Gross Sales by Customer | Customer | Q2 2025 | Q2 2024 | H1 2025 | H1 2024 | | :--- | :--- | :--- | :--- | :--- | | Caremark | 41% | 52% | 43% | 48% | | Accredo | 40% | 33% | 42% | 36% | | Optum | 19% | 15% | 15% | 16% | [Royalty Financing Obligation](index=17&type=section&id=NOTE%206%3A%20Royalty%20Financing%20Obligation) The company has a royalty financing obligation with RTW Investments, L.P. stemming from a $30 million tranche received in August 2023, requiring quarterly payments of 3.75% of worldwide LUMRYZ net product revenue until $75 million is repaid - The company received **$30 million** from RTW and must pay **3.75%** of worldwide LUMRYZ net revenue until a total of **$75 million** is repaid[64](index=64&type=chunk)[65](index=65&type=chunk) Royalty Financing Obligation Activity (in thousands) | Description | June 30, 2025 | | :--- | :--- | | Beginning Balance (Dec 31, 2024) | $37,139 | | Accretion of imputed interest | $4,593 | | Royalty payments made | $(3,859) | | Ending Balance (before current portion) | $37,873 | | Non-current Royalty financing obligation | $35,318 | - Interest expense related to the royalty financing obligation was **$2.4 million** for Q2 2025 and **$4.6 million** for the six months ended June 30, 2025[68](index=68&type=chunk) [Commitments and Contingencies](index=21&type=section&id=NOTE%2012%3A%20Commitments%20and%20Contingencies) This section details the extensive and complex litigation between Avadel and Jazz Pharmaceuticals, involving multiple patent infringement lawsuits and countersuits - In the 'First Jazz Complaint', a jury found Avadel infringed one Jazz patent (U.S. Patent No. 11147782) and awarded damages of **$234**, with a subsequent injunction largely reversed or vacated on appeal by the Federal Circuit in **May 2025**[98](index=98&type=chunk)[102](index=102&type=chunk) - Avadel successfully forced Jazz to delist its REMS Patent (U.S. Patent No. 8731963) from the Orange Book following a court order, which was affirmed on appeal in **February 2023**[93](index=93&type=chunk) - Jazz's lawsuit challenging the FDA's approval of LUMRYZ was dismissed, and the D.C. Court of Appeals affirmed the ruling in **June 2025**, upholding the FDA's approval[140](index=140&type=chunk)[141](index=141&type=chunk) - Avadel has filed its own lawsuits against Jazz, alleging infringement of its patents by Jazz's product XYWAV®, as well as claims of trade secret misappropriation, with these cases ongoing and trial dates set for **2025** and **2028**[120](index=120&type=chunk)[131](index=131&type=chunk)[132](index=132&type=chunk) Consolidated Statements of Income (Loss) Highlights (in thousands) | Metric | Q2 2025 | Q2 2024 | H1 2025 | H1 2024 | | :--- | :--- | :--- | :--- | :--- | | Net product revenue | $68,129 | $41,504 | $120,640 | $68,682 | | Gross profit | $61,763 | $38,716 | $108,697 | $64,372 | | Operating income (loss) | $8,884 | $(12,741) | $5,883 | $(38,776) | | Net income (loss) | $9,665 | $(13,822) | $4,745 | $(41,164) | | Net income (loss) per share - diluted | $0.10 | $(0.14) | $0.05 | $(0.44) | Consolidated Balance Sheet Highlights (in thousands) | Metric | June 30, 2025 | Dec 31, 2024 | | :--- | :--- | :--- | | Cash and cash equivalents | $63,402 | $51,371 | | Total current assets | $159,105 | $134,208 | | Total assets | $187,157 | $164,236 | | Total current liabilities | $57,065 | $48,834 | | Total liabilities | $96,448 | $90,388 | | Total shareholders' equity | $90,709 | $73,848 | Consolidated Statements of Cash Flows Highlights (in thousands) | Metric | H1 2025 | H1 2024 | | :--- | :--- | :--- | | Net cash provided by (used in) operating activities | $4,465 | $(47,890) | | Net cash provided by investing activities | $4,063 | $31,937 | | Net cash provided by financing activities | $1,672 | $13,913 | | Net change in cash and cash equivalents | $12,031 | $(2,320) | [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=32&type=section&id=Item%202.%20Management%27s%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses the company's transition to profitability in Q2 2025, driven by LUMRYZ commercialization, highlighting revenue growth, stable operating expenses, and sufficient liquidity for the next twelve months - The company achieved profitability in Q2 2025 with a net income of **$9.7 million**, a significant turnaround from a net loss of **$13.8 million** in Q2 2024[161](index=161&type=chunk) - Net product revenue for LUMRYZ increased **64.2%** to **$68.1 million** in Q2 2025 compared to Q2 2024, driven by patient growth to approximately **3,100** as of June 30, 2025[162](index=162&type=chunk) - The company initiated the REVITALYZ Phase 3 trial for LUMRYZ in Idiopathic Hypersomnia (IH), with the first patient dosed on **July 31, 2024**, and enrollment expected to complete by the end of **2025**[153](index=153&type=chunk)[154](index=154&type=chunk) - Cash, cash equivalents, and marketable securities increased by **$7.8 million** in the first six months of 2025 to **$81.5 million**, supported by **$4.5 million** in cash from operations[160](index=160&type=chunk) [Results of Operations](index=36&type=section&id=2.1%20Results%20of%20Operations) A detailed analysis of the financial results for the three and six months ended June 30, 2025, compared to the same periods in 2024, showing significant revenue growth, slight gross margin decrease, and shifts in R&D and SG&A expenses Gross Profit Analysis - Six Months Ended June 30 (in thousands) | Metric | 2025 | 2024 | Change $ | Change % | | :--- | :--- | :--- | :--- | :--- | | Net product revenue | $120,640 | $68,682 | $51,958 | 75.7% | | Cost of products sold | $11,943 | $4,310 | $7,633 | 177.1% | | Gross profit | $108,697 | $64,372 | $44,325 | 68.9% | | Gross profit margin | 90% | 94% | - | - | - R&D expenses increased by **$1.5 million (20.9%)** in H1 2025, primarily due to costs for the Phase 3 REVITALYZ clinical trial for LUMRYZ in IH[164](index=164&type=chunk) - SG&A expenses decreased by **$1.8 million (1.9%)** in H1 2025, driven by a **$10.6 million** reduction in legal costs, offsetting increased spending on commercial activities, including higher employee costs (**$5.5M**) and patient/market access costs (**$4.7M**)[166](index=166&type=chunk) [Liquidity and Capital Resources](index=38&type=section&id=2.2%20Liquidity%20and%20Capital%20Resources) The company's liquidity position improved significantly, generating $4.5 million in cash from operations in H1 2025, driven by net income and non-cash adjustments, with management believing existing cash and anticipated revenue are sufficient for the next 12 months Net Cash Flow Summary - Six Months Ended June 30 (in thousands) | Activity | 2025 | 2024 | Change | | :--- | :--- | :--- | :--- | | Operating | $4,465 | $(47,890) | $52,355 | | Investing | $4,063 | $31,937 | $(27,874) | | Financing | $1,672 | $13,913 | $(12,241) | - The company believes its existing cash, cash equivalents, marketable securities, and anticipated cash from LUMRYZ sales provide sufficient capital for at least the next twelve months[175](index=175&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=39&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company outlines its exposure to market risks, primarily interest rate, foreign exchange, and inflation, deeming current impacts immaterial but acknowledging potential future effects on operational costs - Interest Rate Risk: A hypothetical **50 basis point** change in interest rates would not materially impact the fair value of the company's securities due to the short-term nature of the portfolio[177](index=177&type=chunk) - Foreign Exchange Risk: Exposure is primarily from one subsidiary with a euro functional currency, where a **10%** change in the euro exchange rate would have an immaterial impact on net income[178](index=178&type=chunk) - Inflation Risk: The company does not believe inflation had a material effect on its results for the period but acknowledges it could affect future costs for clinical trials, commercialization, and labor[180](index=180&type=chunk) [Controls and Procedures](index=40&type=section&id=Item%204.%20Controls%20and%20Procedures) Management, including the CEO and CFO, evaluated the company's disclosure controls and procedures and concluded they were effective as of June 30, 2025, with no material changes to internal control over financial reporting during the quarter - The CEO and CFO concluded that the company's disclosure controls and procedures were effective as of **June 30, 2025**[181](index=181&type=chunk) - There were no material changes in internal control over financial reporting during the three months ended **June 30, 2025**[182](index=182&type=chunk) [PART II - OTHER INFORMATION](index=40&type=section&id=PART%20II%20-%20OTHER%20INFORMATION) This part covers legal proceedings, updated risk factors, equity sales, and other significant corporate information [Legal Proceedings](index=41&type=section&id=Item%201.%20Legal%20Proceedings) This section incorporates by reference the detailed information on the company's ongoing litigation, primarily with Jazz Pharmaceuticals, as disclosed in Note 12 of the financial statements - Information regarding legal proceedings is incorporated by reference from **Note 12: Commitments and Contingencies - Litigation**[184](index=184&type=chunk) [Risk Factors](index=41&type=section&id=Item%201A.%20Risk%20Factors) This section updates the company's risk factors, emphasizing threats from political and trade instability, intense industry competition, and potential changes in tax law - The company faces significant competition for LUMRYZ from authorized generic versions of Jazz's Xyrem and potential future products, including orexin 2 receptor agonists[188](index=188&type=chunk) - Significant political, trade, or regulatory developments, such as tariffs and changes in U.S. federal policy, could have a material adverse effect on operations[186](index=186&type=chunk) - Changes in tax law, including the 'One Big Beautiful Bill Act' signed on **July 4, 2025**, and the OECD's Pillar Two model rules, could adversely affect the company's business and financial condition[191](index=191&type=chunk)[193](index=193&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=42&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) The company reported no unregistered sales of equity securities during the reporting period - None[195](index=195&type=chunk) [Other Information](index=42&type=section&id=Item%205.%20Other%20Information) The company entered into a new employment agreement with General Counsel Jerad G. Seurer, effective August 6, 2025, and reported no Rule 10b5-1 trading arrangements adopted or modified by directors or officers during Q2 2025 - A new employment agreement was executed with General Counsel Jerad G. Seurer, providing a **$420,000** base salary and a **45%** target bonus[198](index=198&type=chunk)[199](index=199&type=chunk) - During Q2 2025, no company directors or officers adopted, terminated, or modified a Rule 10b5-1 trading arrangement[201](index=201&type=chunk) [Exhibits](index=43&type=section&id=Item%206.%20Exhibits) This section lists all exhibits filed with the Form 10-Q, including new employment agreements and officer certifications - Filed exhibits include new employment agreements for Susan Rodriguez (dated **May 1, 2025**) and Jerad Seurer (dated **August 6, 2025**)[202](index=202&type=chunk) - Certifications from the Principal Executive Officer and Principal Financial Officer pursuant to SEC rules and the Sarbanes-Oxley Act were also filed[202](index=202&type=chunk)

Exhibit 99.1 Nebius reports second quarter financial results and raises ARR guidance for 2025 Amsterdam, August 7, 2025 – Nebius Group N.V. (NASDAQ: NBIS), a leading AI infrastructure company, today announced its unaudited financial results for the second quarter ended June 30, 2025. "Nebius is continuing to deliver exceptional results," said founder and CEO Arkady Volozh. "In Q2 we more than doubled revenue from the previous quarter, and our core business achieved positive Adjusted EBITDA ahead of plan. Be ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 0-16211 DENTSPLY SIRONA Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of (I.R.S. Employer incorporation ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 FORM 10-Q (Mark One) ☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE AC OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40297 N-able, Inc. (Exact name of registrant as specified in its charter) Delaware 85-4069861 (State or other jurisdiction of inco ...

PART I FINANCIAL INFORMATION [Item 1. Financial Statements](index=6&type=section&id=Item%201.%20Financial%20Statements) The company's unaudited condensed consolidated financial statements for the period ended June 30, 2025, show improved net income and increased operating cash flow [Condensed Consolidated Balance Sheets](index=6&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) Condensed Consolidated Balance Sheet Highlights (in thousands) | Account | June 30, 2025 | December 31, 2024 | | :--- | :--- | :--- | | **Total Current Assets** | $420,079 | $394,024 | | Accounts receivable, net | $121,416 | $56,048 | | Inventories | $150,049 | $116,347 | | **Total Assets** | **$2,486,262** | **$2,416,394** | | **Total Current Liabilities** | $103,964 | $62,488 | | Long-term debt, net | $668,439 | $667,774 | | **Total Liabilities** | **$1,307,631** | **$1,259,124** | | **Total Stockholders' Equity** | **$1,178,631** | **$1,157,270** | - The increase in total assets was primarily driven by a significant rise in **accounts receivable** and **inventories**, reflecting seasonal business activity. Total liabilities also increased, mainly due to higher current liabilities including deferred revenue and founders advisory fees payable[13](index=13&type=chunk) [Condensed Consolidated Statements of Operations](index=7&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) Statement of Operations Summary (in thousands, except per share data) | Metric | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :--- | :--- | :--- | :--- | :--- | | Net sales | $162,639 | $127,276 | $234,669 | $186,320 | | Gross profit | $101,496 | $73,267 | $129,649 | $93,969 | | Operating (loss) income | $(26,226) | $45,018 | $51,581 | $(29,846) | | Net (loss) income | $(32,161) | $21,650 | $24,525 | $(60,908) | | Diluted (Loss) EPS | $(0.22) | $0.14 | $0.16 | $(0.42) | - For the six months ended June 30, 2025, the company reported **net income of $24.5 million**, a significant improvement from a net loss of $60.9 million in the prior-year period. This was driven by a **26% increase in net sales** and a substantial decrease in 'Founders advisory fees' expense, which fell from $68.9 million to $16.3 million[16](index=16&type=chunk) - For the three months ended June 30, 2025, the company posted a **net loss of $32.2 million**, compared to a net income of $21.7 million in the same period of 2024. The loss was primarily due to a large **$96.9 million expense for 'Founders advisory fees - related party'**, which reflects the change in fair value of the liability[16](index=16&type=chunk) [Condensed Consolidated Statements of Cash Flows](index=12&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) Cash Flow Summary for the Six Months Ended June 30 (in thousands) | Cash Flow Activity | 2025 | 2024 | | :--- | :--- | :--- | | Net cash provided by operating activities | $20,894 | $11,418 | | Net cash (used in) provided by investing activities | $(42,803) | $187 | | Net cash used in financing activities | $(40,560) | $(14,784) | | **Net change in cash and cash equivalents** | **$(57,798)** | **$(4,114)** | - **Cash from operations increased to $20.9 million** for the first six months of 2025 from $11.4 million in the prior year, despite a significant increase in accounts receivable, aided by higher net income and deferred revenue[23](index=23&type=chunk) - Investing activities used **$42.8 million**, primarily for property and equipment purchases (**$17.6 million**), intangible asset purchases (**$15.2 million**), and a business acquisition (**$10.0 million**)[23](index=23&type=chunk) - Financing activities used **$40.6 million**, dominated by **$40.4 million in common stock repurchases**[23](index=23&type=chunk) [Notes to Condensed Consolidated Financial Statements](index=14&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements) - The company operates in two segments: Fire Safety and Specialty Products. In 2024, approximately **79% of revenues were from the United States**[26](index=26&type=chunk) - On March 28, 2025, the IMS division acquired assets and data rights for certain product lines for **$10.0 million in cash**[36](index=36&type=chunk) - In May 2025, the company settled trade secret litigation with a subsidiary of Compass Minerals International, Inc. and acquired related assets for **$20.0 million**, with **$15.2 million allocated to technology-related intangible assets**[37](index=37&type=chunk) - As of June 30, 2025, the company had **$675.0 million in Senior Notes due 2029** and no outstanding borrowings under its **$100.0 million Revolving Credit Facility**[43](index=43&type=chunk)[52](index=52&type=chunk)[53](index=53&type=chunk) - On May 7, 2025, the Board re-established the limit for common stock repurchases at **$100.0 million**. As of June 30, 2025, **$78.3 million remained available** under the plan[70](index=70&type=chunk) Segment Net Sales (in thousands) | Segment | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :--- | :--- | :--- | :--- | :--- | | Fire Safety | $120,284 | $98,538 | $157,447 | $123,693 | | Specialty Products | $42,355 | $28,738 | $77,222 | $62,627 | | **Total** | **$162,639** | **$127,276** | **$234,669** | **$186,320** | Segment Adjusted EBITDA (in thousands) | Segment | Three Months Ended June 30, 2025 | Three Months Ended June 30, 2024 | Six Months Ended June 30, 2025 | Six Months Ended June 30, 2024 | | :--- | :--- | :--- | :--- | :--- | | Fire Safety | $77,659 | $55,639 | $87,744 | $55,398 | | Specialty Products | $13,679 | $9,269 | $21,677 | $21,646 | | **Total** | **$91,338** | **$64,908** | **$109,421** | **$77,044** | [Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=36&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses financial results, noting a **26% increase in net sales** for the first six months of 2025, a **$24.5 million net income**, and strong liquidity with **$140.7 million cash** [Results of Operations](index=38&type=section&id=Results%20of%20Operations) Consolidated Results - Three Months Ended June 30 (in thousands) | Metric | 2025 | 2024 | Change $ | Change % | | :--- | :--- | :--- | :--- | :--- | | Net sales | $162,639 | $127,276 | $35,363 | 28% | | Gross profit | $101,496 | $73,267 | $28,229 | 39% | | Operating (loss) income | $(26,226) | $45,018 | $(71,244) | (158%) | | Net (loss) income | $(32,161) | $21,650 | $(53,811) | (249%) | - **Q2 2025 net sales increased 28% YoY**, driven by a **$21.7 million increase in the Fire Safety segment** and a **$13.7 million increase in the Specialty Products segment**, including **$9.3 million from recent acquisitions**[112](index=112&type=chunk) - The **Q2 2025 net loss** was driven by a **$96.9 million expense for Founders advisory fees**, reflecting the change in fair value of the liability due to an increase in the company's share price[115](index=115&type=chunk) Consolidated Results - Six Months Ended June 30 (in thousands) | Metric | 2025 | 2024 | Change $ | Change % | | :--- | :--- | :--- | :--- | :--- | | Net sales | $234,669 | $186,320 | $48,349 | 26% | | Gross profit | $129,649 | $93,969 | $35,680 | 38% | | Operating income (loss) | $51,581 | $(29,846) | $81,427 | (273%) | | Net income (loss) | $24,525 | $(60,908) | $85,433 | (140%) | - For the first six months of 2025, **net sales grew 26% YoY**. Fire Safety sales increased by **$33.7 million**, while Specialty Products sales rose by **$14.6 million**, including **$16.9 million from acquisitions**[118](index=118&type=chunk) [Business Segments Performance](index=41&type=section&id=Business%20Segments%20Performance) - **Fire Safety Segment Adjusted EBITDA increased by $22.0 million (39.5%) in Q2 2025** and **$32.3 million (58.3%) in the first six months of 2025** compared to the prior year periods, primarily due to higher net sales[124](index=124&type=chunk)[126](index=126&type=chunk) - **Specialty Products Segment Adjusted EBITDA increased by $4.4 million (47.5%) in Q2 2025**, driven by higher sales from acquisitions. For the first six months, it was relatively flat compared to the prior year[125](index=125&type=chunk)[127](index=127&type=chunk) [Liquidity and Capital Resources](index=42&type=section&id=Liquidity%20and%20Capital%20Resources) - The company believes its existing **cash of $140.7 million**, cash from operations, and availability under its **$100.0 million Revolving Credit Facility** will be sufficient to meet its requirements for at least the next 12 months[133](index=133&type=chunk) - As of June 30, 2025, the company had **no outstanding borrowings** under its Revolving Credit Facility[137](index=137&type=chunk) - During the six months ended June 30, 2025, the company repurchased **3,774,675 shares for $40.4 million** under its Share Repurchase Plan[142](index=142&type=chunk)[151](index=151&type=chunk) - In February 2025, the company settled the 2024 Fixed Annual Advisory Amount by issuing **1,837,304 shares of Common Stock** and paying **$6.7 million in cash**[146](index=146&type=chunk) [Item 3. Quantitative and Qualitative Disclosures About Market Risk](index=45&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) The company is exposed to market risks from foreign currency exchange rates, interest rates on its variable-rate revolving credit facility, and commodity price fluctuations - Primary market risks include **foreign currency fluctuations**, **interest rate changes on variable-rate debt**, and **commodity price volatility**[154](index=154&type=chunk) - Foreign currency exposure is mainly to the **Euro, Canadian dollar, Norwegian krone, and Australian dollar**[155](index=155&type=chunk) - Interest rate risk is tied to the Revolving Credit Facility, which had **no outstanding balance** as of June 30, 2025[156](index=156&type=chunk) [Item 4. Controls and Procedures](index=46&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded that disclosure controls and procedures were effective as of June 30, 2025, with no material changes to internal control over financial reporting - The company's principal executive and financial officers concluded that **disclosure controls and procedures were effective** as of June 30, 2025[160](index=160&type=chunk) - **No material changes** were made to the internal control over financial reporting during the quarter ended June 30, 2025[161](index=161&type=chunk) PART II OTHER INFORMATION [Item 1. Legal Proceedings](index=47&type=section&id=Item%201.%20Legal%20Proceedings) The company is involved in various legal proceedings, including AFFF litigation, but does not expect a material adverse effect on its financials - The company is involved in litigation related to **aqueous film forming foam (AFFF)** but does not expect it to have a material adverse effect[162](index=162&type=chunk) [Item 1A. Risk Factors](index=47&type=section&id=Item%201A.%20Risk%20Factors) No material changes to the company's previously disclosed risk factors were reported since the 2024 Annual Report - **No material changes** to the company's risk factors were reported since the 2024 Annual Report[163](index=163&type=chunk) [Item 2. Unregistered Sales of Equity Securities and Use of Proceeds](index=47&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) The company details common stock repurchases for the quarter ended June 30, 2025, with **2,886,221 shares repurchased** and a re-established **$100.0 million repurchase limit** Common Stock Repurchases for the Quarter Ended June 30, 2025 | Period | Total Shares Purchased | Average Price Paid per Share | | :--- | :--- | :--- | | April 2025 | 1,071,885 | $9.70 | | May 2025 | 1,443,727 | $11.90 | | June 2025 | 370,609 | $12.28 | | **Total** | **2,886,221** | **N/A** | - On May 7, 2025, the Board re-established the limit for Common Stock repurchases at **$100.0 million**. As of June 30, 2025, approximately **$78.3 million remained available** for repurchase[166](index=166&type=chunk) [Other Items (Items 3, 4, 5, 6)](index=47&type=section&id=Other%20Items) Items 3 and 4 are not applicable, Item 5 notes no Rule 10b5-1 trading plan changes, and Item 6 lists report exhibits - **No defaults on senior securities or mine safety disclosures** were reported[167](index=167&type=chunk) - **No officers or directors adopted or terminated a Rule 10b5-1 trading arrangement** during the quarter[168](index=168&type=chunk)

(Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39351 Nuvation Bio Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 85-0862255 ( State or other jurisdiction o ...

Exhibit 99.1 On a same station basis for the quarter ended June 30, 2025 net revenue decreased $1.5 million or 6.4% to $27.6 million and station operating expense decreased 6.4% to $21.7 million. Net revenue decreased 4.7% to $52.4 million for the six-month period ended June 30, 2025 compared to $55.0 million for the same period last year. Station operating expense decreased 3.4% for the six-month period to $44.2 million compared to the same period last year. For the six-month period, we had an operating lo ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2025 OR (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) INDIANA 82-5497352 2500 INNOVATION WAY, GREENFIELD, INDIANA 46140 (Address and zip code of principal executive offices) Registrant's telephone number, including area code (877) 352-6261 ☐ TRAN ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ________________________________________________________________________________________________________________ FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________to ________. Commission File Number: 001 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to ________________ Commission File Number: 001-38371 One Stop Systems, Inc. (Exact Name of Registrant as Specified in its Charter) (State or other ju ...